Published in Food Addit Contam on December 30, 1988
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis (2000) 3.70
Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis (2005) 3.31
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother (1997) 2.99
Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 2.79
Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology (2007) 2.49
Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother (1990) 2.49
High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother (1994) 2.21
The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol (2005) 2.21
Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach. J Infect (1993) 2.10
Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother (1998) 2.04
Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy (2013) 2.03
Antifungal drug resistance in Aspergillus. J Infect (2000) 2.01
Fluconazole-resistant candidosis in an HIV cohort. AIDS (1994) 1.95
Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J (2010) 1.87
Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol (2001) 1.85
Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology (1994) 1.82
Invasive aspergillosis in patients with AIDS. Clin Infect Dis (1994) 1.80
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect (2003) 1.79
Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiol Lett (1995) 1.66
Molecular typing by random amplification of polymorphic DNA and M13 southern hybridization of related paired isolates of Aspergillus fumigatus. J Clin Microbiol (1996) 1.65
Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (2002) 1.61
Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis (2015) 1.61
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis (1992) 1.58
Invasive infection due to penicillium species other than P. marneffei. J Infect (2002) 1.58
Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis (2008) 1.57
Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett (2000) 1.56
Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections. Lab Anim (2003) 1.53
In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp. J Antimicrob Chemother (1993) 1.51
Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother (2000) 1.50
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Peripheral symmetrical gangrene successfully treated with epoprostenol and tissue plasminogen activator. Lancet (1986) 1.44
Aspergillus fungemia: report of two cases and review. Clin Infect Dis (1995) 1.42
New and emerging treatments for fungal infections. J Antimicrob Chemother (2008) 1.42
Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosidase activity. FEBS Lett (1998) 1.42
Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis (1991) 1.40
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother (1997) 1.39
Endemic mycoses: a treatment update. J Antimicrob Chemother (1999) 1.39
Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. J Clin Microbiol (1991) 1.38
Human metabolism of dietary flavonoids: identification of plasma metabolites of quercetin. Free Radic Res (2001) 1.38
CADRE: the Central Aspergillus Data REpository. Nucleic Acids Res (2004) 1.36
Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect (2009) 1.32
Amphotericin B resistance testing of Candida spp.: a comparison of methods. J Antimicrob Chemother (1997) 1.32
Administering amphotericin B--a practical approach. J Antimicrob Chemother (1994) 1.32
Aspergillus wound infection following laparostomy. J Infect (1996) 1.31
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother (2008) 1.31
Invasive yeast infections other than Candida spp. in acute leukaemia. J Hosp Infect (1999) 1.29
Acute myelopathy associated with primary infection with human immunodeficiency virus. Br Med J (Clin Res Ed) (1987) 1.28
Molecular genetics in Aspergillus fumigatus. Curr Opin Microbiol (2000) 1.27
In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother (1998) 1.27
Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice. Med Mycol (2010) 1.26
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother (2006) 1.26
Enzyme-linked immunosorbent assay for Salmonella typhimurium in food: feasibility of 1-day Salmonella detection. Appl Environ Microbiol (1990) 1.24
Scedosporium prolificans, a multi-resistant fungus, from a U.K. AIDS patient. J Infect (1995) 1.23
In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis. Antimicrob Agents Chemother (2000) 1.21
In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother (1998) 1.19
Post-operative aspergillosis. Clin Microbiol Infect (2006) 1.19
Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy (2009) 1.18
Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med (1995) 1.17
Conjugation position of quercetin glucuronides and effect on biological activity. Free Radic Biol Med (2000) 1.17
Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother (1996) 1.15
Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Infect Immun (1996) 1.14
In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother (1998) 1.14
Atypical eumycetoma caused by Phialophora parasitica successfully treated with itraconazole and flucytosine. Br J Dermatol (1997) 1.13
Changes in water and electrolyte balance, plasma volume and composition during pregnancy in the rat. J Physiol (1982) 1.13
Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother (1999) 1.12
Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains. J Clin Microbiol (1997) 1.11
Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother (2001) 1.10
Enzyme-linked immunosorbent assay of ochratoxin A in barley. J Assoc Off Anal Chem (1983) 1.10
Efficacy of oral saperconazole in systemic murine aspergillosis. J Med Vet Mycol (1996) 1.10
In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species. Clin Microbiol Infect (2001) 1.09
Development of surface plasmon resonance-based immunoassay for aflatoxin B(1). J Agric Food Chem (2000) 1.08
Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med (1990) 1.07
When to use fluconazole. Lancet (1995) 1.07
Skin rash after triple vaccine. Arch Dis Child (1987) 1.07
Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole. J Antimicrob Chemother (2001) 1.06
Treatment of coccidioidal meningitis with fluconazole. Rev Infect Dis (1990) 1.06
Excess mortality, length of stay and cost attributable to candidaemia. J Infect (2009) 1.04
Enzyme-Linked Immunosorbent Assays for the Specific and Sensitive Quantification of Methanosarcina mazei and Methanobacterium bryantii. Appl Environ Microbiol (1988) 1.03
Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs. J Med Vet Mycol (1997) 1.03
Bioassay for serum itraconazole concentrations using hydroxyitraconazole standards. Antimicrob Agents Chemother (1994) 1.01
Mannose-binding lectin gene polymorphisms as a susceptibility factor for chronic necrotizing pulmonary aspergillosis. J Infect Dis (2001) 1.00
Cutaneous Mycobacterium thermoresistibile infection in a heart transplant recipient. Rev Infect Dis (1989) 1.00
Unilateral wheeze caused by pseudomembranous aspergillus tracheobronchitis in the immunocompromised patient. Thorax (1993) 1.00
Hormone profiles for progesterone, oestradiol, prolactin, plasma renin activity, aldosterone and corticosterone during pregnancy and pseudopregnancy in two strains of rat: correlation with renal studies. J Endocrinol (1987) 0.99
In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp. Antimicrob Agents Chemother (1995) 0.99
HIV antigenaemia in acute HIV infection. Lancet (1987) 0.98
A phase III study of recombinant human interferon gamma to prevent opportunistic infections in advanced HIV disease. AIDS Res Hum Retroviruses (2001) 0.97
What can comparative genomics tell us about species concepts in the genus Aspergillus? Stud Mycol (2007) 0.96
Candida glabrata oesophagitis in a patient without HIV infection. Eur J Clin Microbiol Infect Dis (2000) 0.96
Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays. Antimicrob Agents Chemother (1996) 0.96
Isolation of Candida norvegensis from clinical specimens: four case reports. Clin Infect Dis (1996) 0.96
Studies on the detrimental effects of bivalent binding in a microtitration plate ELISA and possible remedies. J Immunol Methods (1986) 0.95
An algorithmic approach to aspergillus sinusitis. J Laryngol Otol (1994) 0.95
Invasive aspergillosis: current and future challenges in diagnosis and therapy. Clin Microbiol Infect (2004) 0.95
Diagnosis of infections with Shiga-like toxin-producing Escherichia coli by use of enzyme-linked immunosorbent assays for Shiga-like toxins on cultured stool samples. J Med Microbiol (1994) 0.95
Current trends in the detection of antigenaemia, metabolites and cell wall markers for the diagnosis and therapeutic monitoring of fungal infections. Med Mycol (1998) 0.94
Characterization of a monoclonal antibody specific for HMW subunits of glutenin and its use to investigate glutenin polymers. J Agric Food Chem (2000) 0.94
Candida inconspicua, a fluconazole-resistant pathogen in patients infected with human immunodeficiency virus. Clin Infect Dis (1997) 0.94
In vitro activities of terbinafine against Aspergillus species in comparison with those of itraconazole and amphotericin B. Antimicrob Agents Chemother (2001) 0.94